TG Therapeutics, Inc. has secured a green light in Europe for Briumvi but its commercialization plans for the multiple sclerosis drug remain a mystery.
The European Commission has granted approval of Briumvi (ublituximab) for adults with relapsing forms of MS, just over a couple of months after the European Medicines Agency issued a positive opinion